Evidence map›Paper›PMID 40443118›Full record

ArticleBioconjugate chemistry2025

Multimeric Conjugates Using Engineered Peptide Scaffolds for Efficient siRNA Delivery.

Quentin Vicentini, Dennis Hekman, Deepak Bhatt, Rouven Stulz, Mahya Dezfouli, Peter Gennemark, Nicola Guzzi, Naoko Toki, Bojana Lazovic, Carolina Tängemo and 3 more

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Self-Assembling Short Peptide Carriers for Gene Delivery.International journal of molecular sciences · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Quentin VicentiniCell, Genes and RNA Therapy, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca Gothenburg, 43183 Mölndal, Sweden.ORCID 0009-0006-7659-6164
Dennis HekmanDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden.
Deepak BhattDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden.
Rouven StulzCell, Genes and RNA Therapy, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca Gothenburg, 43183 Mölndal, Sweden.
Mahya DezfouliAssays, Profiling and Cell Sciences, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca, Mölndal, 431 83 Gothenburg, Sweden.
Peter GennemarkDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden.ORCID 0000-0002-7865-7454
Nicola GuzziCentre for Genomics Research, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca, Mölndal, 431 83 Gothenburg, Sweden.
Naoko TokiCentre for Genomics Research, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca, Mölndal, 431 83 Gothenburg, Sweden.
Bojana LazovicCentre for Genomics Research, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca, Mölndal, 431 83 Gothenburg, Sweden.
Carolina TängemoAssays, Profiling and Cell Sciences, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca, Mölndal, 431 83 Gothenburg, Sweden.
Shalini AnderssonCell, Genes and RNA Therapy, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca Gothenburg, 43183 Mölndal, Sweden.
Samir El AndaloussiDivision of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152 Stockholm, Sweden.
Anders DahlénCell, Genes and RNA Therapy, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca Gothenburg, 43183 Mölndal, Sweden.ORCID 0000-0002-2641-7918

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligonucleotide therapeutics (ONT) traditionally involve a single targeting moiety per oligonucleotide when conjugated for organ delivery. Multimerization represents a novel approach by connecting multiple ONTs to a single scaffold, thereby influencing the drug's activity and biophysical properties

Indexed as

Drug Delivery SystemsPeptidesRNA, Small InterferingAcetylgalactosamineAnimalsGene SilencingHepatocytesHumansLiverMiceTissue DistributionAcetylgalactosaminePeptidesRNA, Small Interfering

Identifiers

PMID40443118
PMCPMC12183678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.